Recent Company News

• 08:57 AM ET Jun 11, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:29 PM ET Jul 02, 2026
  

  StreetAccount Sector Summary - China Healthcare June Recap

• 06:04 AM ET Jun 30, 2026
  

  BeOne Medicines announces Phase 3 MANGROVE study of BRUKINSA meets primary endpoint ($289.99, 0.00)

• 11:39 AM ET Jun 29, 2026
  

  China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list

• 07:03 AM ET Jun 26, 2026
  

  EU's CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Ascend GmbH's medicinal product Denosumab Ascend

• 06:04 AM ET Jun 26, 2026
  

  BeOne Medicines subsidiary to make CNY446M tax payment ($275.34, 0.00)

• 07:30 AM ET Jun 11, 2026
  

  BeOne Medicines announces presentation of follow-up data on BRUKINSA in patients with CLL/SLL ($263.61, 0.00)

• 10:57 PM ET Jun 10, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 10:57 AM ET Jun 08, 2026
  

  Transcript Intelligence: BeOne Medicines at Goldman Sachs Global Healthcare Conference ($269.88, -0.22)